EUCTR2007-000275-42-IT进行中（未招募）不适用
A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intensive and high-dose chemo-immunotherapy with autologus pheripherical staminal cells. - IIL/DLCL04
IIL INTERGRUPPO ITALIANO LINFOMI ONLUS0 个研究点目标入组 376 人开始时间: 2007年1月16日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 376
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •61553; Age 18-60 61553; Diagnosis of B DLCL CD 20 new diagnosis or shift from low grade NHL not pre-treated or grade 3b Follicular Lymphoma 61553; Stage II advanced, III, IV with two or more risk factors 61553; Age-adjusted IPI 2-3 61553; PS 3 not due to the lymphoma 61553; Cardiac ejection fraction 45 61553; No impairment of renal, hepatic and pulmonary function 61553; Markers HIV, HBV e HCV negative 61553; HCV if without replication signs, istologically confirmed 61553; AntiHBc , HbsAg-, AntiHBs /- portatori occulti with HBV-DNA negative or weakly positive 61553; Life espectation 3 months 61553; No pregnancy at the start of chemotherapy 61553; Writted informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •61553; Lymphoblastic NHL 61553; Burkitt s Lymphoma 61553; CD20 negative Lymphoma 61553; Follicular or Mantle Lymphoma 61553; Primitive mediastinic Lymphoma with only intrathoracic localization 61553; Age 60 61553; Stage I 61553; Age-adjusted IPI 0-1 61553; PS 3 if not due to the Lymphoma 61553; Creatinine 1.2 mg/dl o creatinine clearance 60 ml/min. 61553; AST/ALT o bilirubine 2.5 the normal value if not due to the Lymphoma. 61553; Serious arterial hypertension not controlled, cardiac arrhythmia not controlled, symptomatic ventricular arrhytmias, congestive heart failure classe NYHA classe III-IV, acute myocardial infarction. 61553; Ventricular ejecton fractionr 45 61553; Important pulmonary disease. Impairment of pulmonary function BPCO, pulmonary fibrosis, TBC 61553; No evidence of active opportunistic infection 61553; HIV positivity 61553; HBV positivity 61553; AntiHBc , HbsAg-, AntiHBs /- with HBV-DNA positive 61553; HCV positivity with active replication signs HCV , PCR , AST 1.5-2x normal 61553; No evidence of symptomatic CNS disease 61553; No prior diagnosis of neoplasm within 3 years, except cervical intraepithelial neoplasia type 1 CIN1 or localized non-melanomatous skin cancer or localized prostatic carcinoma surgically treated, good prognosis DCIS only surgically treated 61553; Pregnancy at the start of chemotherapy 61553; No appropriate contraceptive method in women of childbearing potential or men during the chemotherapy and next six months. 61553; Psychiatric illness precluding understanding concepts of the trial or signing informed consent
研究者
相似试验
招募中
不适用
A phase III, randomized, multi-center study to determine the efficacy of the intercalating combination treatment of chemotherapy and gefitinib or chemotherapy as adjuvant treatment in NSCLC with common EGFR mutationsKCT0003069Yonsei University Health System, Severance Hospital225
进行中（未招募）
不适用
The purpose of the study is to compare and evaluate the generic Brinzolamide ophthalmic suspension with a registered and marketed Brinzolamide ophthalmic suspension as a treatment for ocular hypertension and glaucomaPatients suffering from open angle glaucoma and ocular hypertension with an elevated IOP, higher than 22mmHg and and lower or equal than 35 mmHgEUCTR2011-003692-12-PLAZAD Pharma AG90
进行中（未招募）
1 期
A Phase III multicenter, randomized study with lenalidomide (Revlimid) maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: MCL0208 - IIL-MCL0208Mantle cell lymphomaMedDRA version: 12.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2009-012807-25-PTIIL INTERGRUPPO ITALIANO LINFOMI ONLUS250
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years.Healthy volunteers (Immunisation against diphtheria, tetanus and pertussis)MedDRA version: 19.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-000644-34-Outside-EU/EEAGlaxoSmithKline Biologicals660
已完成
3 期
A clinical trial to assess the efficacy and safety of ?Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed? administered to healthy infants at 6, 10 and 14 weeks of age.CTRI/2012/03/002490Prosper Channel Life Science India Pvt Ltd125